Glioblastoma care in the elderly

Cancer

Volumn 122, Issue 2, 2016, Pages 189-197

  Jordan, Justin T ^a   Gerstner, Elizabeth R ^a   Batchelor, Tracy T ^a   Cahill, Daniel P ^b   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

elderly; glioblastoma; neuro oncology; O(6) methylguanine DNA methyltransferase (MGMT)

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; AGED; BRAIN NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GERIATRIC ASSESSMENT; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; NEEDLE BIOPSY; NEUROSURGERY; PERSONALIZED MEDICINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEUROSURGICAL PROCEDURES; PRECISION MEDICINE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84954075029     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29742     Document Type: Review

References (41)

1. Ostrom QT, Gittleman H, Liao P, et al., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neurooncology. 2014; 16 (suppl 4): iv1-iv63.
2. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
3. Johnson DR, O'Neill BP,. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107: 359-364.
4. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE,. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008; 64: 628-634.
5. Laperriere N, Weller M, Stupp R, et al., Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013; 39: 350-357.
6. Lacroix M, Abi-Said D, Fourney DR, et al., A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190-198.
7. McGirt MJ, Chaichana KL, Gathinji M, et al., Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009; 110: 156-162.
8. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS,. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115: 3-8.
9. Chaichana KL, Garzon-Muvdi T, Parker S, et al., Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011; 18: 239-245.
10. Stark AM, Hedderich J, Held-Feindt J, Mehdorn HM,. Glioblastoma-the consequences of advanced patient age on treatment and survival. Neurosurg Rev. 2007; 30: 56-61; discussion 61-52.
11. Ewelt C, Goeppert M, Rapp M, Steiger HJ, Stummer W, Sabel M,. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol. 2011; 103: 611-618.
12. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J,. Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta Neurochir (Wien). 2003; 145: 5-10.
13. Hoffermann M, Bruckmann L, Kariem Mahdy A, Asslaber M, Payer F, von Campe G,. Treatment results and outcome in elderly patients with glioblastoma multiforme-a retrospective single institution analysis. Clin Neurol Neurosurg. 2015; 128: 60-69.
14. Walker MD, Alexander E Jr, Hunt WE, et al., Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-343.
15. Keime-Guibert F, Chinot O, Taillandier L, et al., Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007; 356: 1527-1535.
16. Roa W, Brasher PM, Bauman G, et al., Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004; 22: 1583-1588.
17. Arvold ND, Tanguturi SK, Aizer AA, et al., Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015; 92: 384-389.
18. Hegi ME, Diserens AC, Godard S, et al., Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Res. 2004; 10: 1871-1874.
19. Esteller M, Garcia-Foncillas J, Andion E, et al., Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343: 1350-1354.
20. Hegi ME, Diserens AC, Gorlia T, et al., MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
21. Piccirilli M, Bistazzoni S, Gagliardi FM, et al,. Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori. 2006; 92: 98-103.
22. Sijben AE, McIntyre JB, Roldan GB, et al., Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol. 2008; 89: 97-103.
23. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT,. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009; 73: 1509-1510.
24. Brandes AA, Franceschi E, Tosoni A, et al., Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009; 115: 3512-3518.
25. Minniti G, Salvati M, Arcella A, et al., Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol. 2011; 102: 311-316.
26. Reifenberger G, Hentschel B, Felsberg J, et al., Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012; 131: 1342-1350.
27. Chinot OL, Barrie M, Frauger E, et al., Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer. 2004; 100: 2208-2214.
28. Gallego Perez-Larraya J, Ducray F, Chinot O, et al., Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011; 29: 3050-3055.
29. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD,. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003; 97: 2262-2266.
30. Minniti G, De Sanctis V, Muni R, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008; 88: 97-103.
31. Minniti G, De Sanctis V, Muni R, et al., Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol. 2009; 91: 95-100.
32. Brandes AA, Vastola F, Basso U, et al., A prospective study on glioblastoma in the elderly. Cancer. 2003; 97: 657-662.
33. Malmstrom A, Gronberg BH, Marosi C, et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13: 916-926.
34. Wick W, Platten M, Meisner C, et al., Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13: 707-715.
35. Minniti G, Scaringi C, Lanzetta G, et al., Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys. 2015; 91: 109-115.
36. Wick W, Weller M, van den Bent M, et al., MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014; 10: 372-385.
37. Preusser M,. MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol. 2009; 24: 511-518.
38. National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers. NCCN Clinical Practice Guidelines in Oncology. Version 1.2015. Fort Washington, PA: NCCN; 2015.
39. Hurria A, Togawa K, Mohile SG, et al., Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29: 3457-3465.
40. Kenis C, Bron D, Libert Y, et al., Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol. 2013; 24: 1306-1312.
41. Kenis C, Decoster L, Van Puyvelde K, et al., Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014; 32: 19-26.